MENLO PARK, Calif., May 16, 2018 /PRNewswire/ -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that,
The accepted abstracts are listed below and are now available online on the ASCO website: https://meetinglibrary.asco.org/.
A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors
Presentation Date & Time: Saturday, June 2, 2018 from 3:24 p.m. – 3:36 p.m. CT (4:24 p.m. – 4:36 p.m. ET)
Oral Session Title: Developmental Therapeutics—Immunotherapy
Abstract Number: 3002
Location: Hall B1, McCormick Place
Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results
Presentation Date & Time: Sunday, June 3, 2018 from 10:57 a.m. – 11:09 a.m. CT (11:57 a.m. – 12:09 p.m. ET)
Oral Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract Number: 7504
Location: E450, McCormick Place
Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas
Presentation Date & Time: Monday, June 4, 2018 8:00 a.m. -11:30 a.m. CT (9:00 a.m. – 12:30 p.m. ET)
Poster Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Abstract Number: 2525
Location: Poster Board 351, Hall A, McCormick Place
About Forty Seven, Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in five clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.
For journalist enquiries please contact Ryan Ferrell at firstname.lastname@example.org or phone (312) 506-5202.
For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at email@example.com or phone (212) 362-1200.
SOURCE Forty Seven, Inc.